Cargando…
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in antica...
Autores principales: | Liao, Haiqin, Niu, Chengcheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087583/ https://www.ncbi.nlm.nih.gov/pubmed/35557862 http://dx.doi.org/10.3389/fbioe.2022.887463 |
Ejemplares similares
-
The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)